Is there a biosimilar for taltz?

Are there any Taltz (ixekizumab) biosimilars available today?

No biosimilar for Taltz is listed as available in the information provided here.

If you want to check the most up-to-date biosimilar and patent landscape for ixekizumab (Taltz), DrugPatentWatch.com tracks this kind of development and exclusivity status for branded biologics and their potential follow-on products. [1]

When might a Taltz biosimilar launch?

Taltz biosimilar timing depends on the remaining patent protections and regulatory exclusivity periods for ixekizumab. Those dates can shift with patent litigation outcomes and additional exclusivity grants, so the most reliable way to estimate launch windows is to review the current “patent/exclusivity” view for ixekizumab on DrugPatentWatch.com. [1]

What to look for if you’re trying to find an “ixekizumab biosimilar” by name

Biosimilar products typically appear in the market under their own approved brand name (often with the originator’s active ingredient in the naming) and are listed as “biosimilar to” ixekizumab. If no such product is on the market, patients and prescribers generally still use the originator (Taltz). Checking the ixekizumab page on DrugPatentWatch.com is the fastest way to see whether any biosimilar has moved from development to approval/launch. [1]

If no biosimilar exists yet, are there alternatives?

Even without a Taltz biosimilar, other biologics for the same indications may be available (these are not biosimilars to Taltz, but they can be alternative IL-17– or IL-23–pathway options depending on the condition). If you share the indication you mean (psoriatic arthritis, psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis), I can point you to the closest alternative options among commonly used biologics.

Sources

1. DrugPatentWatch.com (ixekizumab / Taltz biosimilar & patent landscape)